Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Potential Pilgrims Aged 56 Years and Older in Turkey
Condition: Healthy Volunteers (Meningococcal Infection) Intervention: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine) Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ActHIB | Men | Meningitis | Meningitis Vaccine | Middle East Health | Research | Tetanus | Tetanus Vaccine | Turkey Health | Vaccines